CAMP4 Therapeutics Corporation Payments of Debt Issuance Costs
CAMP4 Therapeutics Corporation (CAMP) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-03-05
- CAMP4 Therapeutics Corporation payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CAMP4 Therapeutics Corporation payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CAMP4 Therapeutics Corporation payments of debt issuance costs for the quarter ending 2024-12-31 was $3.16M.
- CAMP4 Therapeutics Corporation payments of debt issuance costs for the quarter ending 2024-09-30 was $212.00K.
- CAMP4 Therapeutics Corporation payments of debt issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation payments of debt issuance costs for fiscal 2024 was $3.98M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.37M derived: sum of 2 quarters · filed 2026-03-05 | $3.98M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $820.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $608.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |